Trevena, Inc. (TRVN) Given New $7.00 Price Target at HC Wainwright

Trevena, Inc. (NASDAQ:TRVN) had its price objective cut by stock analysts at HC Wainwright from $8.00 to $7.00 in a research note issued to investors on Thursday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 195.36% from the company’s previous close.

TRVN has been the topic of a number of other research reports. Zacks Investment Research downgraded Trevena from a “hold” rating to a “sell” rating in a research report on Wednesday, July 26th. Oppenheimer Holdings, Inc. set a $8.00 price target on Trevena and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Finally, Cowen and Company reissued a “buy” rating and set a $10.00 price target on shares of Trevena in a research report on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the company’s stock. Trevena currently has an average rating of “Buy” and a consensus target price of $10.48.

Shares of Trevena (NASDAQ TRVN) opened at 2.37 on Thursday. The stock’s 50 day moving average price is $2.49 and its 200 day moving average price is $2.75. Trevena has a 1-year low of $2.15 and a 1-year high of $8.00. The company’s market cap is $141.48 million.

Trevena (NASDAQ:TRVN) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.35). Equities research analysts forecast that Trevena will post ($1.41) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2017/10/12/trevena-inc-trvn-given-new-7-00-price-target-at-hc-wainwright.html.

Several large investors have recently modified their holdings of the company. California State Teachers Retirement System boosted its holdings in shares of Trevena by 0.5% during the second quarter. California State Teachers Retirement System now owns 97,107 shares of the biopharmaceutical company’s stock worth $223,000 after acquiring an additional 500 shares during the period. American International Group Inc. boosted its holdings in shares of Trevena by 7.1% during the first quarter. American International Group Inc. now owns 27,541 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 1,816 shares during the period. Teachers Advisors LLC boosted its holdings in shares of Trevena by 6.2% during the fourth quarter. Teachers Advisors LLC now owns 77,523 shares of the biopharmaceutical company’s stock worth $456,000 after acquiring an additional 4,505 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Trevena by 12.1% during the first quarter. Goldman Sachs Group Inc. now owns 59,522 shares of the biopharmaceutical company’s stock worth $218,000 after acquiring an additional 6,402 shares during the period. Finally, Rhumbline Advisers boosted its holdings in shares of Trevena by 30.1% during the second quarter. Rhumbline Advisers now owns 64,251 shares of the biopharmaceutical company’s stock worth $148,000 after acquiring an additional 14,880 shares during the period. Institutional investors own 60.09% of the company’s stock.

Trevena Company Profile

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Analyst Recommendations for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply